Investigating Different Types of Cinnamon in Iran with Attention to Its Toxicity and Contamination

Introduction: The present research is a resource-based retrospective study with reference to conducted studies and the results of the cinnamon study by referring to various foods and attaries (groceries) factories such as Golha, Bartar, Yekoyek, and Hati Kara companies in Iran has been answered to the questions related to probable toxicity of cinnamon. Methods and results: In this study, which is both a research and library study for this research topic, referring to sites, articles, journals, and various search engines including Science Direct and Google Scholar and SCOPUS, provide necessary information in regard to cinnamon types, cinnamon history, Cinnamon advantages and disadvantages, types of cinnamon ingredients, were found to be the cause of the toxicity of the probable types of cinnamon, and the results obtained that were related to the subject. According to the obtained data, it was found that cinnamomum zeylanicum bloom (Cinnamomum verum J. Presl) is less common (0-486 mg/kg) and (190 mg/kg)  also it is known as a good cinnamon for cinnamon cassia (Chinese) (Cinnamomum aromaticum Nees or Cinnamomum cassia (L) J. Presl) (coumarin is between 40 and 12180 mg / kg in the sample) and 700 mg/kg, and in Iran, abundance, import and use of cinnamon zeylanicum (Ceylon) is more than the other. Conclusions: According to obtain results, it was not proved camarin hepatic toxicity among the whole population and highest sensitivity was observed among people with previous hepatic disease, its daily use (permissible use on a daily basis is 1.5 mg/kg). With regard to this fact that in Iran, cinnamon as is used a flavoring of food and medicine, and the frequency of more Indian cinnamon (Ceylon , zeylanicum) than other cats in market due to higher quality. It can be concluded that with the max daily usage is (for a person body weight 60 kg) 1.5 mg of comarin per day, humans may be exposed to its complications, and that in Iran cinnamon species, which is most commonly used for cinnamomum zeylanicum cinnamon food, medicine (diabetes, etc.) and in various industries, and that it is not possible to enter this amount of comarin per day through the use of cinnamon to the body, it can be said that Iran is not exposed to the (probable) toxicside effects

ANALYTICAL METHOD VALIDATION, PHARMACOKINETICS AND BIOEQUIVALENCE STUDY OF DIMETHYL FUMARATE IN HEALTHY IRANIAN VOLUNTEERS

Objective: Pharmacokinetic evaluation of Dimethyl Fumarate (DMF) in the Iranian population wasn’t studied. So, the aim of this research is the validation of the analytical method and evaluation of the pharmacokinetic properties and bioequivalence of the generic form of this drug versus the reference product. Methods: 2 single-dose, test, and reference DMF products were orally administered to 24 healthy volunteers. The washout period was 28 d between the treatments. Monomethyl fumarate as the metabolite of DMF was analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and the method was validated. Also, the pharmacokinetic parameters were calculated for bioequivalence evaluation. Results: The analytical method was validated and linear over the range of 31.25-4000 ng/ml (R2= 0.997). In addition, the method was precise and accurate in the low, medium, and high concentrations. The results indicated that the 2 products had similar pharmacokinetics. Further, the 90% CI of the mean ratios of the test versus the reference products of the log-transformed area under the concentration-time curve over 10 h (0.99 to 1.02) and peak concentration (0.98 to 1.03) were within the acceptable range of 0.8 to 1.25 and the generic product of DMF could be similar to that of the reference product. Conclusion: The applied analytical method is selective, accurate, precise, and repeatable for the analysis of monomethyl fumarate (MMF) in plasma. Also, the bioequivalence study showed no significant difference between the pharmacokinetic parameters of these 2 products. So, the DMF test product can be claimed to be bioequivalent with the reference product

Determination of Scientific Name of Bitter “Qust”: an Important Controversial Plant Source in the Iranian Medicinal Plants Market for Neurological Complications

Background and objectives: Traditional medicine could provide a hopeful area of research to mitigate the suffering of patients. “Qust” is one of the medicinal plants that are mentioned in Persian Medicine (PM) for treatment of neurological diseases. There is diversity within the scientific name of “Qust” in different references. Some have introduced Saussurea costus (Falc.) Lipsch. (Asteraceae), while others have presented Costus speciosus (J. Koenig) Sm. (Costaceae) as “Qust”. Since “Qust” is not endemic in Iran, there is difficulty to access to the whole plant for its identification. Hence, this study has aimed to identify available bitter “Qust” which is composed of roots of the plant in the Iranian market. Methods: Macroscopic characters and microscopic properties of powders and transverse sections of specimens with essential oil analysis of the Indian and one of the Iran herbal market samples using chromatography-mass spectrometry (GC-MS) were investigated for identification of bitter “Qust”. Results: Microscopic evaluation showed presence of secretory cavities and their specific size, narrow radial rows of conducting tissue alternating with broad medullary rays in the secondary phloem and xylem, presence of inulin, absence of starch and calcium oxalate crystals in the bitter “Qust” particles. Further, positive response was observed to S. costus identifying test. In the analysis of essential oils, active components of S. costus, such as dehydrocostus lactone, were identified in the examined essential oils. Conclusion: According to the results, it could be concluded that bitter “Qust” in Iran herbal market most probably is S. costus

Preparation of Oxymel (Sekanjabin-e) Buzuri Syrup as Vascular Opener (Mofatteh) Product and Its Standardization

Background: Sekanjabin-e buzuri consisting extracts of Chicorium intybus L. (Kasni), Cuscuta chinensis Lam. (Koshus), Apium graveolens L. (Karafs) and Pimpinella anisum L. (Anison) seeds is a Traditional Persian Medicine product. These drugs have many applications in traditional medicine, but they are more effective in opening vascular obstructions and related functions, especially in cardiovascular system. Purpose: In this study we prepared a proper Sekanjabin-e buzuri and developed a HPLC method for analysis of chlorogenic acid (CGA), as an herbal marker compound, for quality control and standardization in both Sekanjabin-e buzuri syrup and its ingredient sources. Methods: Sekanjabin-e buzuri is a group of oxymels that have many different formulations. A proper formulation has chosen from literature (from Gharabadin-e-salehi) and prepared. For standardization of Sekanjabin-e buzuri we developed a method for detecting chlorogenic acid content. A reversed phase MZ C18 column (150*3.0 mm, 5µm) using a mixture of acetonitrile-phosphoric acid 0.1% with gradient elution program for 20 minutes with flow rate of 1.5 ml/min with UV detection at 330 nm. Results: The chlorogenic acid Rt =5.1 minutes and linear over the range of 0.2-1.5 µg/ml, (R2 = 0.9996). The calculated LOD and LOQ of chlorogenic acid were 0.02 and 0.06 µg/ml, respectively. The concentration of chlorogenic acid was 7.69, 10.37, 2.25, 2.88 and 22.86 µg/ml for Chicorium intybus L., Cuscuta chinensis Lam., Apium graveolens L. and Pimpinella anisum L. seeds and Sekanjabin-e buzuri syrup, respectively. Conclusion: This standardized Sekanjabin-e buzuri syrup will be used as a vascular opener (Mofatteh) complementary product for opening internal organs obstruction e.g. promoting cardiovascular health.</jats:p

Targeting Atherosclerotic Plaque in Avicenna’s View

Objective: Cardiovascular disease (CVD) including atherosclerosis is currently the most common cause of death in the world. Atherosclerosis can be treated by a vast variety of modalities: from lifestyle modification to invasive open surgical bypass procedures. Regarding the limitations of conventional medicine, worldwide attention to complementary and alternative medicines has increased because of their holistic approach, lower cost and better public access. In this move towards Integrative Medicine -besides other traditional schools of medicine-Persian Medicine (PM) with its long historical background should be considered as a suitable source for research. Method: In this study we investigated major traditional literature of PM, Avicenna’s “Al-Qanun fi al-Tibb” [The Canon of medicine], to find suitable treatment modalities of atherosclerosis in comparison to conventional methods. Result: In the quest for a concept close to atherosclerosis, “sodde” (meaning obstruction) seems to be equal to atherosclerosis and “Mofattehaat” as opener drugs with different types including “Mohallelaat” (dissolvers) and “Moghatteaat” (cutting agents) have been recommended to remove the obstructing materials. Recent studies indicate that many of the medicinal herbs which were introduced as opener drugs by Avicenna have potential pharmacological effects on managing atherosclerosis. Conclusion: Scientific evidence confirm the efficacy of traditional herbs for elimination of atheroma. Antiobstructive traditional medicines are similar to the conventional atherectomy in targeting atheroma by removing atherosclerotic plaque directly, but they are non-invasive, user-friendly, much cheaper and probably with less side effects.</jats:p

ANALYTICAL METHOD VALIDATION, PHARMACOKINETICS AND BIOEQUIVALENCE STUDY OF DIMETHYL FUMARATE IN HEALTHY IRANIAN VOLUNTEERS

Objective: Pharmacokinetic evaluation of Dimethyl Fumarate (DMF) in the Iranian population wasn’t studied. So, the aim of this research is the validation of the analytical method and evaluation of the pharmacokinetic properties and bioequivalence of the generic form of this drug versus the reference product. Methods: 2 single-dose, test, and reference DMF products were orally administered to 24 healthy volunteers. The washout period was 28 d between the treatments. Monomethyl fumarate as the metabolite of DMF was analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and the method was validated. Also, the pharmacokinetic parameters were calculated for bioequivalence evaluation. Results: The analytical method was validated and linear over the range of 31.25-4000 ng/ml (R2= 0.997). In addition, the method was precise and accurate in the low, medium, and high concentrations. The results indicated that the 2 products had similar pharmacokinetics. Further, the 90% CI of the mean ratios of the test versus the reference products of the log-transformed area under the concentration-time curve over 10 h (0.99 to 1.02) and peak concentration (0.98 to 1.03) were within the acceptable range of 0.8 to 1.25 and the generic product of DMF could be similar to that of the reference product. Conclusion: The applied analytical method is selective, accurate, precise, and repeatable for the analysis of monomethyl fumarate (MMF) in plasma. Also, the bioequivalence study showed no significant difference between the pharmacokinetic parameters of these 2 products. So, the DMF test product can be claimed to be bioequivalent with the reference product.</jats:p

ANALYTICAL METHOD VALIDATION AND BIOEQUIVALENCE STUDY OF ERLOTINIB 150 MG TABLETS IN IRANIAN HEALTHY VOLUNTEERS UNDER FASTING CONDITION

Objective: This study aims to compare a generic formulation of the drug erlotinib 150 mg tablet to the brand-name version to validate the analytical method and bioequivalence studies. Methods: Erlotinib hydrochloride tablets (test versus reference formulation) were compared in a randomized, two-period crossover study to determine their pharmacokinetic properties and bioequivalence in healthy Iranian volunteers. 14 days passed between each treatment during the washout period. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to analyze erlotinib, and the method validation is presented. Results: Over the range of 6.25- 3200 ng/ ml, the analytical method was verified as linear (R2= 0.998). The technique was also accurate and precise at various concentrations. The results showed that the pharmacokinetics of the two products were comparable. Following administration of the test and reference products, the geometric averages for (Area under the curve) AUC0-72, AUCinf, and maximum plasma concentration (Cmax) were 104.71 (90% CI, 93.39-117.40), 104.68 (90% CI, 93.47-117.23), and 104.85 (90% CI, 94.61-116.21), respectively. The outcomes fell within the permitted tolerance of 0.8 to 1.25. Conclusion: For the determination of erlotinib in plasma, the used analytical approach is accurate, precise, repeatable, and selective. Additionally, the bioequivalence research revealed no appreciable differences in pharmacokinetic characteristics between the reference and test products. Therefore, it is possible to assert that the generic erlotinib product and the reference product are bioequivalent

ANALYTICAL METHOD VALIDATION AND BIOEQUIVALENCE STUDY OF ERLOTINIB 150 MG TABLETS IN IRANIAN HEALTHY VOLUNTEERS UNDER FASTING CONDITION

Objective: This study aims to compare a generic formulation of the drug erlotinib 150 mg tablet to the brand-name version to validate the analytical method and bioequivalence studies. Methods: Erlotinib hydrochloride tablets (test versus reference formulation) were compared in a randomized, two-period crossover study to determine their pharmacokinetic properties and bioequivalence in healthy Iranian volunteers. 14 d passed between each treatment during the washout period. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to analyze erlotinib, and the method validation is presented. Results: Over the range of 6.25-3200 ng/ml, the analytical method was verified as linear (R2= 0.998). The technique was also accurate and precise at various concentrations. The results showed that the pharmacokinetics of the two products were comparable. Following administration of the test and reference products, the geometric averages for (Area under the curve) AUC0-72, AUCinf, and maximum plasma concentration (Cmax) were 104.71 (90% CI, 93.39-117.40), 104.68 (90% CI, 93.47-117.23), and 104.85 (90% CI, 94.61-116.21), respectively. The outcomes fell within the permitted tolerance of 0.8 to 1.25. Conclusion: For the determination of erlotinib in plasma, the used analytical approach is accurate, precise, repeatable, and selective. Additionally, the bioequivalence research revealed no appreciable differences in pharmacokinetic characteristics between the reference and test products. Therefore, it is possible to assert that the generic erlotinib product and the reference product are bioequivalent.</jats:p

Effect of Volume and Renewal of the Storage Media on the Release of Monomer from Dental Composites

This study evaluated the effect of the volume and renewing of storage media on monomer leachability from dental composite. Samples of two dental composites (BEAUTIFIL II Gingiva (BG) and Filtek Bulk-Fill Flowable (FBF)) were stored after polymerization in 1 and 3 milt storage media (ethanol/water 75%) for seven days. Refreshing of storage media was done in half of the samples of each group. The amounts of releasing monomers (UDMA, BisGMA, TEGDMA) in storage media were measured by high-performance liquid chromatography (HPLC). Data was analyzed using two-way ANOVA and t-test (α = 0.05). Elution of TEGDMA and UDMA from both composites was significantly higher in 3 mL storage media. In groups with refreshing of storage media, BisGMA had higher amounts of release. Saturation makes the storage media volume important factor in monomer elution. Refreshing of storage media had significant effect on monomer release before the elution of 50% of total released monomer

Effect of Volume and Renewal of the Storage Media on the Release of Monomer from Dental Composites

Abstract Background: released monomers to the oral environment from dental composite, cause systemic or local side effects on the tissues and cells and also affect mechanical properties of the resins.Methods: This study evaluated the effect of the volume and renewing of storage media on monomer leachability from dental composite. Samples of two dental composites (BEAUTIFIL II Gingiva (BG) and Filtek bulkfill flowable (FBF)) were stored after polymerization in 1 and 3 milt storage media (ethanol/water 75%) for seven days. Refreshing of storage media was done in half of the samples of each group. The amount of releasing monomers (UDMA, BisGMA, TEGDMA) in storage media were measured by high performance liquid chromatography. (HPLC) Data was analyzed using Two-way ANOVA and T-test. (α=0.05).Results: Elution of TEGDMA and UDMA from both composites was significantly higher in 3ml storage media. In groups with refreshing of storage media, BisGMA had higher amounts of release. Saturation makes the storage media volume important factor in monomer elution. Conclusion: Refreshing of storage media had significant effect on monomer release before the elution of 50% of total released monomer.</jats:p